Background Povetacicept (ALPN-303) is an Fc fusion protein of a variant, engineered TACI domain, which mediates significantly more potent inhibitory activity than WT TACI-Fc or BAFF- or APRIL-specific ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune ...

Artificial intelligence and machine learning applications are emerging as transformative technologies in medicine. With greater access to a diverse range of big datasets, researchers are turning to ...

Objectives To evaluate what proportion of patients fulfil the DORIS definition of remission, the definition of lupus low disease activity state (LLDAS) and LLDAS with a glucocorticoid (GC) dosage ≤5 ...

SLE is characterised by an activation of the interferon (IFN) system, which leads to an increased expression of IFN-regulated genes. The reasons behind the IFN signature in SLE are (1) the existence ...

Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA ...

Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established ...

Objective B cell function and autoantibodies are important in SLE pathogenesis. In this work, we aimed to investigate the impact of cumulative SLE B cell genetics on SLE subphenotype and autoantibody ...

Objectives To evaluate the performance of Systemic Lupus Erythematosus Risk Probability Index (SLERPI) in patients with SLE using a Chinese cohort. Methods The Chinese cohort included 352 patients ...

Objective To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort. Methods Multicentre, longitudinal study of a cohort of ...

Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment-associated toxicities and slowing or ...